Loading clinical trials...
Loading clinical trials...
A Phase II, Single-Site, Double-Blind, Placebo-Controlled Randomized Withdrawal Study Assessing the Efficacy and Safety of Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis
Conditions
Interventions
Sarilumab
Placebo
Locations
1
United States
Stanford University
Palo Alto, California, United States
Start Date
September 3, 2019
Primary Completion Date
July 26, 2022
Completion Date
September 9, 2022
Last Updated
October 5, 2023
NCT04402086
NCT07359690
NCT06573723
NCT06510894
NCT05374447
NCT06978725
Lead Sponsor
Stanford University
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions